The findings of a large US real-world cohort (n= 18,000) study, published in 2024, show that patients on tirzepatide were significantly more likely to achieve 5 %, 10 % and 15 % weight loss compared with semaglutide (HR 1.76, 2.54, 3.24, respectively), with a 12-month mean weight difference of -6.9% 8
GLP-1 agonists commonly cause nausea, vomiting, diarrhea, and abdominal painsymptoms that overlap with Crohn's disease
doi: 10.1016/j.jmb.2021.167280 184 ChaudharySYadavRPKumarSYadavSC
If more than 5 days have passed, skip your dose and continue with your next schedule
The pill and the injection are not different drugs with different chemistry
Factors Researchers Typically Consider Researchers generally weigh the strength and consistency of existing published data when scoping a study around one of these three compound classes